Live Breaking News & Updates on Kumar Visvanathan

Stay updated with breaking news from Kumar visvanathan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

South Africa , United States , New South Wales , South African , Jennifer Macdiarmid , Kumar Visvanathan , Himanshu Brahmbhatt , Most Innovative Company In Drug Delivery , Nanotech Companies To , Innovative Company , Nanocell Technology , Innovative Program In Healthcare , Professor Kumar Visvanathan , Principal Investigator , Most Innovative Company , Drug Delivery , Australian Financial Review , Innovative Program ,

Australian research project investigating long-term impact of COVID-19 awarded 2021 Gilead Fellowship Grant


Gilead Sciences
• Five diverse research projects spanning COVID-19, HIV, hepatitis C elimination, CAR T cell therapy and fungal infections are the 2021 recipients of the Gilead Fellowship Research Grant.
• Now in its 11th year, the Fellowship has granted more than $2.6 million to research projects throughout Australia which often struggle to secure funding or face high competition.
Melbourne, 29 June 2021 – Gilead Sciences Australia today announced the five recipients of the 2021 Gilead Fellowship Research Grants Program one of which will investigate the medium- and long-term impacts of COVID-19 on patients’ health and wellbeing.
Grant recipient Professor Kumar Visvanathan, Infectious Diseases Physician, Academic Lead of Medicine at the University of Melbourne campus and Co-Director of the Immunology Research Centre at St Vincent’s Hospital, Melbourne will follow almost 100 individuals with confirmed COVID-19 infection over a six month period to look at C ....

Paul Slade , Benjamin Bavinton , Kumar Visvanathan , Gilead Sciences Australia Fellowship Research Grants Program , Immunology Research Centre At St Vincent Hospital , Gilead Sciences Australia , Affairs Gilead Sciences , Senior Research , Prevention Program , Biobehavioural Prevention Research Group , University Of Melbourne , Group Leader , Gilead Fellowship Research Grant , Kirby Institute , Gilead Fellowship Research Grants Program , Gilead Fellowship Research , Fellowship Research Grants Program , Professor Kumar Visvanathan , Infectious Diseases Physician , Academic Lead , Immunology Research Centre , Hospital Melbourne , Professor Visvanathan , Fellowship Grant , Senior Research Fellow , Senior Director Medical Affairs Gilead Sciences ,